Published by linker 5
Posted on February 25, 2021
According to the latest research by the company, the global frontotemporal disorders treatment market is expected to be valued at US$ 451.4 Mn, by 2028 end. The report on the frontotemporal disorders treatment market projects major growth potential with average year-on-year growth rate of 4.7% through 2028.
The increasing funding by the governments across the globe for R&D is projected to be the major factor expected to propel the growth of the frontotemporal disorders treatment market over the forecast period. Government organizations such as the National Institute of Aging (NIA), National Institute of Neurological Disorders and Strokes (NINDS) and National Institute of Health (NIH) are conducting research and development support programs and making efforts to advance therapeutic development in neurological diseases. The growing number of dementia cases has increased the population base of frontotemporal dementia, which is expected to propel the demand for frontotemporal dementia drugs and medications. Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market.
Increasing funding and grants by the various non-profit organizations for drug development is also expected to boost the growth of the frontotemporal disorders treatment market. Research funding initiatives by non-profit organization such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, CurePSP, Inc. have helped to promote FTD research initiatives.
Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-5033
However, lack of approved drugs for frontotemporal disorder treatment is expected to negatively impact the growth of the frontotemporal disorders treatment market. Moreover, the high failure rate of clinical trials and studies is also a major factor expected to hamper the growth of the frontotemporal disorders treatment market.
The company has segmented the global frontotemporal disorders treatment market based on drug class, treatment type, disease indication, distribution channel, and regions. Based on drug class, the frontotemporal disorders treatment market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. The cognitive enhancers segment is expected to contribute high revenue share in global frontotemporal disorders treatment market. By treatment type, the frontotemporal disorders treatment market is segmented into behavioral symptom management and psychological symptoms management segment.
The behavioral symptom management segment is expected to contribute high value share in the global frontotemporal disorders treatment market. Based on disease indication, the frontotemporal disorders treatment market is segmented into frontotemporal dementia, primary progressive aphasia, and movement disorders segment. In terms of revenue, the frontotemporal dementia segment is projected to hold significant share in the global frontotemporal disorders treatment market over the forecast period. Based on distribution channels, the frontotemporal disorders treatment market is segmented into hospital pharmacies, retail pharmacy, drug stores, and online pharmacy. The retail pharmacy segment is expected to contribute high value share in the global frontotemporal disorders treatment market.
Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/customization-available/rep-gb-5033
On the basis of region, the global frontotemporal disorders treatment market has been segmented into North America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Latin America and the Middle East & Africa. Western Europe is expected to contribute large revenue share in the global frontotemporal disorders treatment market over the forecast period. The demand for frontotemporal disorders treatment has increased in Western Europe due to the increasing prevalence of frontotemporal dementia as well as growing number of clinical studies in the region. North America is expected to contribute second large revenue share in the global frontotemporal disorders treatment market. The Asia Pacific Excluding Japan (APEJ) is projected to witness significant growth due to increasing per capita expenditure and government initiatives for the treatment of neurological disorders.
The report tracks some of the key manufacturers operating in the global frontotemporal disorders treatment market. The players included in the report are Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, GlaxoSmithKline Plc., Novartis AG, Mylan N.V., Merck & Company, Inc., AstraZeneca plc, and Allergen plc, among others.
Explore more articles in the Research Reports category
